NanoViricides, Inc. (NYSE:NNVC – Get Free Report) was up 1.7% during mid-day trading on Friday . The stock traded as high as $1.28 and last traded at $1.23. Approximately 86,721 shares traded hands during trading, a decline of 66% from the average daily volume of 254,003 shares. The stock had previously closed at $1.21.
Wall Street Analyst Weigh In
Separately, StockNews.com downgraded NanoViricides from a “hold” rating to a “sell” rating in a research report on Monday, November 18th.
Get Our Latest Stock Report on NNVC
NanoViricides Price Performance
Institutional Trading of NanoViricides
Large investors have recently added to or reduced their stakes in the company. Integrated Wealth Concepts LLC raised its stake in NanoViricides by 44.8% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 53,335 shares of the company’s stock valued at $80,000 after purchasing an additional 16,500 shares during the period. Renaissance Technologies LLC raised its stake in NanoViricides by 26.8% during the 4th quarter. Renaissance Technologies LLC now owns 145,700 shares of the company’s stock valued at $208,000 after purchasing an additional 30,800 shares during the period. Geode Capital Management LLC increased its stake in shares of NanoViricides by 28.7% in the fourth quarter. Geode Capital Management LLC now owns 143,313 shares of the company’s stock worth $205,000 after acquiring an additional 31,956 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of NanoViricides in the fourth quarter worth $91,000. 10.30% of the stock is owned by institutional investors and hedge funds.
About NanoViricides
NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.
Featured Articles
- Five stocks we like better than NanoViricides
- When to Sell a Stock for Profit or Loss
- How to Build the Ultimate Everything ETF Portfolio
- How to Calculate Inflation Rate
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- What is the Nasdaq? Complete Overview with History
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.